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Objective. The aim of this study was to compare retinal nerve ﬁber layer thickness (RNFLT) between spectral-domain (SD-)
and time-domain optical coherence tomography (TD-OCT) in MS patients and healthy controls (HC). Furthermore, RNFLT
between MS eyes with and without optic neuritis (ON) and HC should be explored. Finally, the relationship between RNFLT,
disease duration, EDSS, and disease modifying therapy (DMT) should be established. Design. Prospective, cross-sectional study.
Participants.28MSpatientsand35HC.Methods.BothgroupsunderwentTD-andSD-OCTmeasurements.RFNLTwascorrelated
between the two machines and between MS eyes with and without ON and HC. Furthermore, RNFLT was correlated to disease
duration, EDSS and DMT. Results. A strong correlation (Pearson’s r = 0.921, P<0.001), but a statistically signiﬁcant diﬀerence
of 2µm( P<0.001), was found between the two devices. RNFLT was signiﬁcantly diﬀerent between MS eyes with history of
ON (mean RFNLT (SD) 72.21µm (15.83µm)), MS eyes without history of ON 93.03µm (14.25µm), and HC 99.07µm (7.23µm)
(P<0.001).Conclusions.ThemeasurementsbetweendiﬀerentgenerationofOCTmachinesarenotinterchangeable,whichshould
be taken into account if comparing results between diﬀerent machines and switching OCT machine in longitudinal studies.
1.Introduction
Optical coherence tomography (OCT) is a noninvasive
technique for high-resolution, cross-sectional tomographic
imaging of retinal tissue using backscattered light. OCT
imaging is very similar to ultrasound B-Scan imaging but
uses infrared-light instead of ultrasound waves. Two-dimen-
sional, cross-sectional images are obtained from multiple
axial scans (A-Scans) at diﬀerent transverse locations [1].
Until recently, third-generation time-domain OCT (TD-
OCT) using Stratus OCT (Carl Zeiss Meditec AG, Jena,
Germany) has been widely used to acquire images at a rate of
400 axial scans per second with an axial resolution of 10µm
[2]. The recently introduced fourth-generation spectral-
domain OCT (SD-OCT) has improved depth resolution by
a factor of three (axial resolution up to 3.8µm) and allows a
signiﬁcantly higher acquisition speed (40’000 axial scans per
second) resulting in improved image quality and minimized
motion artefacts [3]. Furthermore, software improvements
allow reconstruction of a three-dimensional image of the
retina.
Heidelberg Spectralis OCT (Heidelberg Engineering,
Heidelberg,Germany)usesanintegratedeyetrackingsystem
(IETS) to compensate for eye movement artefact during data
acquisition. IETS also allows an automatic re-centration,
which can be used for more reliable follow-up scans.2 Journal of Ophthalmology
Heidelberg noise reduction technology helps producing
signiﬁcantlyimprovedimagesbyadjustingdataandreducing
noise using mean values from several scans [4]. Heidelberg
Spectralis OCT needs to be validated for accuracy, repro-
ducibility, and comparability to previous models before it
can be reliably used for clinical and research purposes.
Recent studies have shown diﬀerences between SD-OCT
machines (Cirrus SD-OCT, Carl Zeiss Meditec AG, Jena,
Germany [5–10], RTVue-100, Optovue Inc., Fremont, CA,
USA [11], and Spectralis, Heidelberg Engineering, Heidel-
berg, Germany, [12, 13]) and TD-OCT in healthy controls
and glaucoma patients. These studies showed better repro-
ducibility compared to TD-OCT and signiﬁcant diﬀerences
in RNFLT measurements between the two generations of
machines.
So far only few studies have examined the role of SD-
OCT in multiple sclerosis (MS) patients [14, 15]. Therefore,
our speciﬁc study aims are (1) to compare retinal nerve
ﬁber layer thickness (RNFLT) measurements between the
validated third-generation Stratus OCT and the new fourth-
generation Heidelberg Spectralis OCT in MS patients and
healthy controls, (2) to compare RNFLT between MS eyes
aﬀected by optic neuritis (ON eyes) to eyes without a history
of ON (NON eyes) and control eyes, and ﬁnally (3) to
determine the relationship between RNFLT, disease dura-
tion, expanded disability status scale (EDSS), and disease-
modifying therapy (DMT) in MS patients and refraction in
both groups.
2.MaterialsandMethods
2.1. Study Design and Patient Population. In a prospective,
cross-sectional study, subjects with MS and controls were
identiﬁed from the UBC Hospital MS Clinic with the
aid of advertisement and pamphlets. All MS subjects had
conﬁrmed diagnosis of MS made by a neurologist with
speciﬁc experience in managing MS patients, and based on
the modiﬁed McDonald criteria [16].
2.2. Inclusion and Exclusion Criteria. Patients with a recent
history of optic neuritis (ON) (<6 months), history of
ocular diseases (age-related macular degeneration, diabetic
retinopathy, uveitis, and glaucoma), and history of other
diseases that could mimic MS or aﬀect OCT testing (neu-
romyelitisoptica,parkinson’sdisease,andAlzheimerdisease)
a n ds u b j e c t sw i t hd i ﬃculties maintaining ﬁxation were not
included.
2.3. Outcome Measures
2.3.1. Clinical Data. Clinical history information such as
disease duration from time of disease onset, previous history
of optic neuritis, and other neurological information like
EDSS score was obtained by history and from hospital charts
after patient recruitment. Myopia was deﬁned as spherical
equivalent of <−0.50 diopters, emmetropia between −0.5
and +0.5 diopters, and hyperopia as >+0.5 diopters mea-
sured by SD-OCT.
Table 1: Descriptive statistics of MS and control group.
Control
group MS group
N 35 28
Mean age in years (±SD) 38.88 (11.65) 43.46 (9.08)
Gender 15 female
20 male
23 female
5m a l e
Number excluded 2 1
Average RNFL SD-OCT
(micrometer ± SD) 98.59 (6.74) 88.80 (17.39)
Average RNFL TD-OCT
(micrometer ± SD) 100.67 (8.88) 90.91 (18.09)
Number of eyes with optic neuritis n/a 14 (26%)
Number of patients with SPMS n/a 3 (11%)
Mean EDSS (SD) n/a 2.8 (1.6)
Mean disease duration in months
(SD) n/a 83.12 (83.67)
On disease-modifying therapy n/a 52% (14/27)
2.3.2. Optical Coherence Tomography. OCT was performed
inarandomorderbyanexperiencedpersonthatwasmasked
to clinical data, using TD-OCT and SD-OCT within one-
hour period with no pupil dilation (half of subjects had TD-
OCT prior to SD-OCT and vice versa).
TD-OCT (Stratus OCT 3000, Software Version 4.0.7;
Carl Zeiss Meditec, Jena, Germany): the standard Fast RNFL
acquisition protocol was used. Three scans, each composed
of 256 A scans, were automatically acquired consecutively
using a circle scan with a standardized diameter of 3.4mm
by the same experienced operator. Several scans were taken
and the best-centered scan with a quality score of ≥6w a s
chosen for analysis (as suggested by the manufacturer). An
automated computer algorithm delineated the anterior and
posterior margins of the RNFL.
SD-OCT (Heidelberg Spectralis OCT, Software Version
5.1.2, Heidelberg Engineering, Heidelberg, Germany): The
RNFL protocol in high-resolution mode (axial resolution
3.8µm, 19’000 scans per second) was used. Sixteen consec-
utive circular B-scans (each composed of 1536 A scans) with
a diameter of 3.4mm were automatically averaged to reduce
speckle noise. The online tracking system compensated
for eye movements. Several scans were taken by the same
experienced operator and the best centered with a quality of
atleast24(whichisabouttheequivalentof6inStratusOCT)
was chosen for analysis. The included software algorithm
delineated the anterior and posterior margins of the RNFL.
2.4. Statistical Analysis. Microsoft Oﬃce 2007 and SPSS
Version 16.0 for Windows were used to do statistical analysis.
Descriptive, mean comparison (t-test and one-way ANOVA)
and correlation analysis (Pearson’s) were used to compare
OCT measures between diﬀerent groups: SD-OCT versus
TD-OCT RNFLT measurements; MS eyes versus control
eyes;myopicversusemmetropicandhyperopiceyes.P values
less than 0.05 were considered to be statistically signiﬁcant.Journal of Ophthalmology 3
Table 2: Diﬀe r e n c e si nR N F L Tb e t w e e nS D -a n dT D - O C Ti nM Sg r o u pa n dc o n t r o lg r o u p( S D - O C Tm i n u sT D - O C T ) .
Control group MS group
Mean diﬀerence in µm
(95% CI) Pearson’s Corr r Mean diﬀerence in µm
(95% CI) Pearson’s Corr r
Average −2.40 (−3.70 to −1.09) 0.83 (P<0.001) −1.69 (−3.44 to 0.06) 0.93 (P<0.001)
Superior 3.75 (0.99 to 6.51) 0.77 (P<0.001) 5.54 (2.20 to 8.87) 0.90 (P<0.001)
Temporal 0.04 (−1.41 to 1.50) 0.88 (P<0.001) −0.54 (−3.02 to 1.94) 0.87 (P<0.001)
Inferior −6.56 (−8.28 to −4.84) 0.85 (P<0.001) −6.81 (−9.51 to −4.11) 0.91 (P<0.001)
Nasal −6.93 (−9.47 to −4.38) 0.80 (P<0.001) −3.37 (−7.13 to 0.40) 0.81 (P<0.001)
3. Results
3.1. Patient Demographics and Clinical Characteristics. The
study recruitment took place between August 2009 and
February 2010. Twenty-eight MS patients (age mean:
38.88yrs; SD: 11.65yrs, mean disease duration: 83.12
months, SD: 83.76; 25 with relapsing-remitting and 3 with
secondary progressive MS; EDSS range between 1.5 and 6.5,
mean: 2.8, SD: 1.6) and 35 healthy controls (age mean:
43.46yrs; SD: 9.08yrs) participated in this study (Table 1).
Fourteen (out of 27) patients used DMT for MS. Sixteen
(out of 27) patients had an EDSS score of less than 3.0. All
subjectswereexaminedbySD-OCTandTD-OCTmachines.
Two subjects were excluded in the control group due to (1)
software failure to delineate RNFL correctly and (2) OCT
artefacts due to high myopia. One patient in the MS group
was excluded due to inability to measure exact refraction
after refractive surgery. Out of the remaining 120 eyes 32
eyesweremyopic(refractionrangebetween −8.25and −0.75
diopters), 74 eyes were emmetropic (refraction = 0 diopters),
and14eyeswerehyperopic(refractionrangebetween+1and
+6 diopters). Fourteen (out of 54) MS eyes were previously
aﬀected by a single optic neuritis event.
3.2. Comparing Time-Domain and Spectral-Domain OCT.
SD-OCT and TD-OCT RNFLT values were strongly corre-
lated in all quadrants with correlation coeﬃcient ranging
from 0.808 (P<0.01) in inferior quadrant to 0.878
(P<0.01) in temporal quadrant. The overall RNFLT was
also strongly correlated (correlation coeﬃcient = 0.921;
P<0.001) between the two machines (Figure 1). However,
RNFLT values showed minor but statistically signiﬁcant
diﬀerences between the two machines (P<0.001) (Table 2).
3.3. Comparing RNFLT Measurements between MS and Con-
trol Eyes. Overall, MS patients had signiﬁcantly lower
RNFLT measured by both SD-OCT and TD-OCT (Table 3).
Moreover, RNFLT was signiﬁcantly diﬀerent between MS
eyes with history of optic neuritis (mean RFNL (SD)
72.21µm (15.83µm)), MS eyes without history of optic
neuritis 93.03µm (14.25µm), and healthy controls 99.07µm
(7.23µm) (P<0.001) measured by SD-OCT (Figure 2).
3.4. Correlation between Retinal Nerve Fiber Layer Thickness,
Disease Duration, EDSS, DMT, and Refraction. When all MS
eyes were considered, duration of the disease since onset of
RNFLT in TD-OCT
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Figure 1: Correlation between average RNFLT in µmi nS D - O C T
(y-axis) and TD-OCT (x-axis).
ﬁrst symptoms weakly correlated with superior (r =− 0.28;
P = 0.048) and temporal (r =− 0.33; P = 0.02) quadrant
RNFLT. There was no signiﬁcant correlation between disease
duration and mean RNFLT values (r =− 0.13; P = 0.35),
or RNFLT values in the inferior (r =− 0.14; P = 0.31) or
nasal (r =− 0.19; P = 0.17) quadrants. When only MS
eyes without a history of ON were considered, a moderate
correlation (r =− 0.44; P = 0.01) was found between mean
RNFLTanddiseaseduration,withasigniﬁcantcorrelationin
the superior and inferior quadrants (r =− 0.51; P = 0.001,
andr =− 0.38;P = 0.02,resp.)andnosigniﬁcantcorrelation
in the temporal and nasal quadrants (P = 0.91 and P = 0.08,
resp.).
When EDSS was correlated to mean RNFLT in all MS
eyes, a weak correlation was found (r =− 0.3; P = 0.05).
This was signiﬁcant in the superior quadrant only (r =
−0.33; P = 0.02), nonsigniﬁcant in the other quadrants
(P = 0.46 for temporal quadrant, P = 0.07 for inferior
quadrant, and P = 0.39 for nasal quadrant). When only MS
eyes without a history of ON were considered, a moderate
correlation was found between EDSS and mean RNFLT (r =
−0.35; P = 0.03). This was also signiﬁcant in the superior
(r =− 0.38; P = 0.02) and inferior quadrants (r =− 0.33;
P = 0.05), but not in the temporal (P = 0.31) and nasal
quadrants (P = 0.43).4 Journal of Ophthalmology
Table 3: Overview RNFLT between SD- and TD-OCT in MS and control groups, separated by quadrants.
SD-OCT µm mean (SD) TD-OCT µm mean (SD)
Control MS Control MS
Average 98.59 (6.79) 88.80 (17.55) 100.67 (8.96) 90.9107 (18.26)
Superior 121.27 (16.22) 107.25 (26.95) 117.48 (16.87) 101.88 (27.04)
Temporal 71.17 (10.88) 65.02 (15.92) 70.86 (12.88)∗ 65.82 (17.57)∗
Inferior 127.16 (13.10) 114.80 (21.64) 133.23 (13.59) 120.36 (27.08)
Nasal 74.55 (11.21) 68.07 (21.53) 81.031 (15.75) 72.20 (24.34)
∗All measures are signiﬁcantly diﬀerent between MS patients and control except for temporal quadrant measured by TD-OCT.
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Figure 2: Boxplot of diﬀerences between RNFLT in control group
(left box, group 1) and groups of MS eyes without optic neuritis
(center box, group 2) and MS eyes with optic neuritis (left box,
group 2) measured by SD-OCT.
The minimal diﬀerence between RFNLT in patients with
DMT (86.07µm) and without DMT (90.82µm) was not
statistically diﬀerent (P = 0.327).
Myopic and emmetropic eyes showed signiﬁcantly
diﬀerent RFNLT measurements in both SD-OCT (mean
RNFLT (SD) 87.75µm (12.52µm) versus 96.46µm
(14.61µm)) and TD-OCT (89.59µm (13.65µm) versus
99.19µm (15.11µm)). There was a signiﬁcant correlation
between refraction in diopters and RNFLT (r = 0.4; P =
0.005).
4. Discussion
The main aim of this study was to compare RNFLT mea-
surements between SD-OCT and TD-OCT in MS patients
and healthy controls. Our results show strong correlations
(Pearson’s r = 0.921) between the measurements of the
Heidelberg Spectralis SD-OCT and TD-OCT. RNFLT values
were signiﬁcantly lower in SD-OCT (mean diﬀerence 2µm).
These results are similar to those of Watson et al. [14], who
found Spectralis SD-OCT to measure 3µm lower than TD-
OCT in a study of 50 MS eyes, and Seibold et al. [12],
who found the same results in a series of 80 healthy eyes.
On the other hand, Arthur et al. [13] compared Spectralis
SD-OCT with TD-OCT in 30 healthy eyes and found
Spectralis to measure 6µm lower, a larger diﬀerence than
our results. Studies using other SD-OCT devices showed
similar discrepancies with Cirrus SD-OCT measuring lower
RNFLT and RTVue measuring higher RNFLT than TD-OCT
(Table 4).
The discrepancy between diﬀerent devices may be
explained by a diﬀerence in calibration due to a higher
resolution and improved software algorithm in more recent
models [6]. This has been addressed in evaluation of SD-
OCT in macular thickness [17, 18]. The phenomenon
of thickness-dependent interdevice diﬀerences was not
observed in our data [15]. The minimal diﬀerence observed
in our study is lower than the axial resolution of the
SD-OCT, hence clinically not signiﬁcant. However, results
from these machines cannot be interchangeably interpreted
in a population study and ongoing longitudinal studies
switching generation of OCT should take these diﬀerences
into consideration.
There has been increasing interest in RNFLT measure-
ments in MS patients in order to determine whether OCT
can be used as a surrogate marker for follow-up exami-
nations. Therefore, a large amount of cross-sectional data
has been previously published. Many studies have shown
diﬀerences between RNFLT in MS eyes with optic neuritis,
MS eyes without optic neuritis, and healthy controls, for
example, [15, 19–27]. All these studies were using the
older TD-OCT technology. We were able to reproduce these
diﬀerences using the newer generation of OCT machine.
Spectral-domain OCT has several advantages over the older
TD-OCT technology: there is no pupil dilation needed, the
speed of the machines is higher, reducing the possibilities of
motion artefacts, and the lack of the previously used bright
ﬂashlight makes the examination much more comfortable
for the patient. Furthermore, the higher resolution and
the improved software algorithm allowing automatic re-
centration for follow-up exams help in improving accuracyJournal of Ophthalmology 5
Table 4: Overview published studies comparing RNFLT in SD-OCT versus TD-OCT.
Author SD-OCT used Study population
(eyes) Results
Chang et al. [5] Cirrus 54 glaucoma
50 controls
Cirrus is equivalent to Stratus for
detecting glaucoma
Knight et al. [6] Cirrus 101 glaucoma
29 controls
Cirrus 7µm lower then Stratus in both
groups
Leung et al. [7] Cirrus 83 glaucoma
97 controls
Cirrus 12µm lower for control, 6µm
lower in glaucoma
Sung et al. [8] Cirrus 103 glaucoma
60 controls
Cirrus 13µm lower for control, 14µm
lower in glaucoma
Vizzeri et al. [9] Cirrus 78 glaucoma
32 controls
Cirrus 8µm lower for control, 6µml o w e r
in glaucoma
Kim et al. [10] Cirrus 27 controls Cirrus 10µml o w e r
Gonzalez-Garcia et al. [11] RTVue-100 76 glaucoma
60 controls RTVue 2 µm higher
Seibold et al. [12] Cirrus, Spectralis, RTVue-100 80 controls Spectralis 3µm lower, Cirrus 12µm
lower, RTVue 3µm higher,
Arthur et al. [13] Spectralis 30 controls Spectralis 6µml o w e r
Watson et al. [14] 3D OCT-1000, Cirrus, RTVue-100, Spectralis 50 MS
Spectralis 3µml o w e r ,C i r r u s8µml o w e r ,
RTVue 3 µm higher, 3D OCT-1000 2µm
higher
Bock et al. [15] Cirrus 110 MS Cirrus 8µml o w e r
and reproducibility for follow-up exam in longitudinal stud-
ies. Up to date, no longitudinal study in an MS cohort has
been published using SD-OCT technology. Two longitudinal
studies using TD-OCT have not been able to show any
change in RNFLT in a two-year follow-up period [27, 28].
Only Talman et al. [21] could detect signiﬁcant RNFLT
changes in a 4.5-year study of 299 patients using TD-OCT
(loss of 2.9µm at 2 to 3 years and 6.1µma t3t o4 . 5y e a r s ;
P<0.001). This pattern was observed in both eyes with
and without history of ON. Proportions of eyes with RNFL
loss greater than test-retest variability (≥6.6µm) increased
from 11% at baseline to 44% at ﬁnal visit (3–4.5 years)
(P<0.001). The progressive axonal loss of approximately
2µm per year could only be detected over a relatively long
period of time. This is most likely due to the relatively low
resolution of the TD-OCT machine. The new generation
SD-OCT is more sensitive to smaller changes and may be
more reliable detecting RNFL changes over shorter time
periods. Longitudinal studies using SD-OCT technology will
be needed to establish if OCT measurements can be used as
a surrogate marker in MS and be used to monitor disease
progression and disease-modifying therapy.
We were interested in contribution of disease duration,
EDSS, refraction, and status of DMT on RNFLT measure-
ments. Our results showed no signiﬁcant correlation for
disease duration and EDSS when all MS eyes were compared
but moderate correlation when only eyes without a history
of ON were considered. This may be due to the fact that ON
causes a 18–22% loss of RNFLT and the small progressive
loss of RNFLT is not evident at this time anymore [29].
The diﬀerence between patients with and without DMT was
statistically not signiﬁcant, but our sample size was too small
for a ﬁnal conclusion.
WealsocomparedRNFLTmeasurementsbetweenrefrac-
tion range groups (described in methods). We showed a
relatively large diﬀerence between myopic and nonmyopic
eyes using both devices. Thinner RNFLT measurements in
myopes may be explained by increased scan diameter due
to the telecentric optics of the OCT in increased myopia
and myopic tilted discs resulting in elevated and decreased
RNFLT at diﬀerent sites. Furthermore, the centration is very
diﬃcultevenonafrozenfundusimageduetotheasymmetry
of the disc.
RNFLT values were signiﬁcantly lower in myopic eyes
as the diameter of the scan increases with higher myopic
refraction. Rauscher et al. [30]h a v er e p o r t e da na v e r a g e
decrease of RNFL of 3µm per diopter of myopia. A possible
explanationisthetelecentricsystem,whichkeepstheangleof
the OCT beam constant at 12 degrees. In our measurements,
the scan diameter increased to 3.8mm in −5 diopters and
to 4.2mm in −10 diopters. This results in thinning of about
10µmi n−5 diopters and about 20µmi n−10 diopters [31].
This was not a major issue with the older TD-OCT as the
axial resolution is only 10µm but gets more importance with
the SD-OCT devices with higher resolution up to 3.8µm.
This must be taken into consideration designing future
studies. Higher myopic refraction should be excluded or
properly matched between groups. Furthermore, normative
databases are needed to be refraction adjusted.
The main aim of the study was not to characterize
RNFLT in MS population. Therefore, the MS population
involved was randomly selected and examiner was not
blinded to subjects’ diagnosis and history of optic neuritis.
Furthermore, the groups were not gender- or age-matched
and both eyes of each subject were included. However, this
was not a major issue in comparing RNFLT in the same6 Journal of Ophthalmology
subject between two diﬀerent machines and did not aﬀect
the results of our main study aim.
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